A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection

Cost ofMedical carePediatric respiratory diseasesRespiratory infections in childrenTreatment

For young readers